Half-year report · HY

Period2026-01-01 → 2026-06-30
Filed2026-08-07
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 46
MetricValuePeriodScopeSource row
Revenue¥1.22T2026-01-01 → 2026-06-30Cons.Revenue IFRS
Revenue¥2.43T2025-01-01 → 2025-12-31Cons.Revenue IFRS (5-year summary)
Revenue¥1.14T2025-01-01 → 2025-06-30Cons.Revenue IFRS
Operating income¥129.0bn2026-01-01 → 2026-06-30Cons.Operating profit loss IFRS
Operating income¥68.7bn2025-01-01 → 2025-06-30Cons.Operating profit loss IFRS
Profit before tax¥150.9bn2026-01-01 → 2026-06-30Cons.Profit loss before tax IFRS
Profit before tax¥237.9bn2025-01-01 → 2025-12-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥83.8bn2025-01-01 → 2025-06-30Cons.Profit loss before tax IFRS
Net income (owners)¥101.7bn2026-01-01 → 2026-06-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥147.5bn2025-01-01 → 2025-12-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥52.8bn2025-01-01 → 2025-06-30Cons.Profit loss attributable to owners of parent IFRS
Net income¥116.1bn2026-01-01 → 2026-06-30Cons.Profit loss IFRS
Net income¥60.5bn2025-01-01 → 2025-06-30Cons.Profit loss IFRS
Total assets¥3.40Tat 2026-06-30Cons.Assets IFRS
Total assets¥3.49Tat 2025-12-31Cons.Assets IFRS
Total assets¥3.30Tat 2025-06-30Cons.Total assets IFRS (5-year summary)
Total liabilities¥1.72Tat 2026-06-30Cons.Liabilities IFRS
Total liabilities¥1.90Tat 2025-12-31Cons.Liabilities IFRS
Net assets / equity¥1.68Tat 2026-06-30Cons.Equity IFRS
Net assets / equity¥1.60Tat 2025-12-31Cons.Equity IFRS
Net assets / equity¥1.41Tat 2025-06-30Cons.Equity IFRS
Net assets / equity¥1.53Tat 2024-12-31vCons.Equity IFRS
Equity (owners)¥1.36Tat 2026-06-30Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥1.29Tat 2025-12-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥1.12Tat 2025-06-30Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥168.1bnat 2026-06-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥125.3bnat 2025-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥132.4bnat 2025-06-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥118.6bnat 2024-12-31vCons.Cash and cash equivalents IFRS
Operating cash flow¥137.3bn2026-01-01 → 2026-06-30Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥295.4bn2025-01-01 → 2025-12-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥67.3bn2025-01-01 → 2025-06-30Cons.Net cash provided by used in operating activities IFRS
Investing cash flow¥53.7bn2026-01-01 → 2026-06-30Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥185.0bn2025-01-01 → 2025-12-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥61.6bn2025-01-01 → 2025-06-30Cons.Net cash provided by used in investing activities IFRS
Financing cash flow−¥162.5bn2026-01-01 → 2026-06-30Cons.Net cash provided by used in financing activities IFRS
Financing cash flow−¥110.5bn2025-01-01 → 2025-12-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow¥35.8bn2025-01-01 → 2025-06-30Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥126.332026-01-01 → 2026-06-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥182.132025-01-01 → 2025-12-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥65.232025-01-01 → 2025-06-30Cons.Basic earnings loss per share IFRS
EPS (diluted)¥182.132025-01-01 → 2025-12-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥65.222025-01-01 → 2025-06-30Cons.Diluted earnings loss per share IFRS
Equity ratio40.0%at 2026-06-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio36.8%at 2025-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio34.0%at 2025-06-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 46
SegmentItemPeriodValue
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2026-01-01 → 2026-06-30¥46.3bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2026-01-01 → 2026-06-30¥12.8bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2026-01-01 → 2026-06-30¥33.4bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2026-01-01 → 2026-06-30−¥1.5bn
Reconciling Itemsreconcilingrevenue2026-01-01 → 2026-06-30−¥38.9bn
Reconciling Itemsreconcilingrevenue intersegment2026-01-01 → 2026-06-30−¥38.9bn
Reconciling Itemsreconcilingsegment profit2026-01-01 → 2026-06-30−¥34.2bn
Alcoholic Beveragesreportable segmentrevenue2026-01-01 → 2026-06-30¥519.1bn
Alcoholic Beveragesreportable segmentrevenue external2026-01-01 → 2026-06-30¥517.8bn
Alcoholic Beveragesreportable segmentrevenue intersegment2026-01-01 → 2026-06-30¥1.3bn
Alcoholic Beveragesreportable segmentsegment profit2026-01-01 → 2026-06-30¥62.1bn
Health Sciencereportable segmentrevenue2026-01-01 → 2026-06-30¥131.1bn
Health Sciencereportable segmentrevenue external2026-01-01 → 2026-06-30¥128.8bn
Health Sciencereportable segmentrevenue intersegment2026-01-01 → 2026-06-30¥2.3bn
Health Sciencereportable segmentsegment profit2026-01-01 → 2026-06-30¥10.4bn
Non Alcoholic Beveragesreportable segmentrevenue2026-01-01 → 2026-06-30¥296.7bn
Non Alcoholic Beveragesreportable segmentrevenue external2026-01-01 → 2026-06-30¥294.9bn
Non Alcoholic Beveragesreportable segmentrevenue intersegment2026-01-01 → 2026-06-30¥1.8bn
Non Alcoholic Beveragesreportable segmentsegment profit2026-01-01 → 2026-06-30¥31.0bn
Pharmaceuticalsreportable segmentrevenue2026-01-01 → 2026-06-30¥263.6bn
Pharmaceuticalsreportable segmentrevenue external2026-01-01 → 2026-06-30¥263.5bn
Pharmaceuticalsreportable segmentrevenue intersegment2026-01-01 → 2026-06-30¥139m
Pharmaceuticalsreportable segmentsegment profit2026-01-01 → 2026-06-30¥60.5bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2025-01-01 → 2025-06-30¥47.0bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2025-01-01 → 2025-06-30¥14.1bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2025-01-01 → 2025-06-30¥32.9bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2025-01-01 → 2025-06-30−¥591m
Reconciling Itemsreconcilingrevenue2025-01-01 → 2025-06-30−¥38.3bn
Reconciling Itemsreconcilingrevenue intersegment2025-01-01 → 2025-06-30−¥38.3bn
Reconciling Itemsreconcilingsegment profit2025-01-01 → 2025-06-30−¥30.0bn
Alcoholic Beveragesreportable segmentrevenue2025-01-01 → 2025-06-30¥493.8bn
Alcoholic Beveragesreportable segmentrevenue external2025-01-01 → 2025-06-30¥492.6bn
Alcoholic Beveragesreportable segmentrevenue intersegment2025-01-01 → 2025-06-30¥1.2bn
Alcoholic Beveragesreportable segmentsegment profit2025-01-01 → 2025-06-30¥53.2bn
Health Sciencereportable segmentrevenue2025-01-01 → 2025-06-30¥129.7bn
Health Sciencereportable segmentrevenue external2025-01-01 → 2025-06-30¥127.2bn
Health Sciencereportable segmentrevenue intersegment2025-01-01 → 2025-06-30¥2.5bn
Health Sciencereportable segmentsegment profit2025-01-01 → 2025-06-30¥8.6bn
Non Alcoholic Beveragesreportable segmentrevenue2025-01-01 → 2025-06-30¥273.4bn
Non Alcoholic Beveragesreportable segmentrevenue external2025-01-01 → 2025-06-30¥271.8bn
Non Alcoholic Beveragesreportable segmentrevenue intersegment2025-01-01 → 2025-06-30¥1.6bn
Non Alcoholic Beveragesreportable segmentsegment profit2025-01-01 → 2025-06-30¥29.5bn
Pharmaceuticalsreportable segmentrevenue2025-01-01 → 2025-06-30¥230.7bn
Pharmaceuticalsreportable segmentrevenue external2025-01-01 → 2025-06-30¥230.5bn
Pharmaceuticalsreportable segmentrevenue intersegment2025-01-01 → 2025-06-30¥156m
Pharmaceuticalsreportable segmentsegment profit2025-01-01 → 2025-06-30¥33.5bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 869
ItemContextValueUnit
Loss gain on sale and retirement of property plant and equipment and intangible assets ope cf IFRSInterimDuration2166000000JPY
Gain on sale of shares of subsidiaries ope cf IFRSPrior1InterimDuration-JPY
Gain on sale of shares of subsidiaries ope cf IFRSInterimDuration-29033000000JPY
Gain on liquidation of subsidiaries ope cf IFRSPrior1InterimDuration-JPY
Gain on liquidation of subsidiaries ope cf IFRSInterimDuration-14173000000JPY
Decrease increase in trade receivables ope cf IFRSPrior1InterimDuration56520000000JPY
Decrease increase in trade receivables ope cf IFRSInterimDuration114970000000JPY
Decrease increase in inventories ope cf IFRSPrior1InterimDuration-18509000000JPY
Decrease increase in inventories ope cf IFRSInterimDuration-9111000000JPY
Increase decrease in trade payables ope cf IFRSPrior1InterimDuration-38812000000JPY
Increase decrease in trade payables ope cf IFRSInterimDuration-31019000000JPY
Increase decrease in liquor taxes payable ope cf IFRSPrior1InterimDuration-26744000000JPY
Increase decrease in liquor taxes payable ope cf IFRSInterimDuration-29808000000JPY
Increase decrease in deposits received ope cf IFRSPrior1InterimDuration574000000JPY
Increase decrease in deposits received ope cf IFRSInterimDuration2165000000JPY
Other changes in working capital ope cf IFRSPrior1InterimDuration-21889000000JPY
Other changes in working capital ope cf IFRSInterimDuration-58884000000JPY
Subtotal ope cf IFRSPrior1InterimDuration67377000000JPY
Subtotal ope cf IFRSInterimDuration141666000000JPY
Interest and dividends received ope cf IFRSPrior1InterimDuration17662000000JPY
Interest and dividends received ope cf IFRSInterimDuration22927000000JPY
Interest paid ope cf IFRSPrior1InterimDuration-4289000000JPY
Interest paid ope cf IFRSInterimDuration-6040000000JPY
Income taxes paid ope cf IFRSPrior1InterimDuration-13497000000JPY
Income taxes paid ope cf IFRSInterimDuration-21204000000JPY
Net cash provided by used in operating activities IFRSPrior1InterimDuration67253000000JPY
Net cash provided by used in operating activities IFRSInterimDuration137349000000JPY
Purchase of property plant and equipment and intangible assets inv cf IFRSPrior1InterimDuration-72241000000JPY
Purchase of property plant and equipment and intangible assets inv cf IFRSInterimDuration-65255000000JPY
Proceeds from sale of property plant and equipment and intangible assets inv cf IFRSPrior1InterimDuration1221000000JPY
Proceeds from sale of property plant and equipment and intangible assets inv cf IFRSInterimDuration156000000JPY
Purchase of investments inv cf IFRSPrior1InterimDuration-674000000JPY
Purchase of investments inv cf IFRSInterimDuration-2462000000JPY
Proceeds from sales of investments inv cf IFRSPrior1InterimDuration315000000JPY
Proceeds from sales of investments inv cf IFRSInterimDuration778000000JPY
Proceeds from sale of shares of subsidiaries inv cf IFRSPrior1InterimDuration-JPY
Proceeds from sale of shares of subsidiaries inv cf IFRSInterimDuration5361000000JPY
Proceeds from transfer of membership interests of subsidiaries inv cf IFRSPrior1InterimDuration-JPY
Proceeds from transfer of membership interests of subsidiaries inv cf IFRSInterimDuration114479000000JPY
Purchase of investments accounted for using equity method inv cf IFRSPrior1InterimDuration-JPY
Purchase of investments accounted for using equity method inv cf IFRSInterimDuration-18000000JPY
Proceeds from sale of businesses inv cf IFRSPrior1InterimDuration16872000000JPY
Proceeds from sale of businesses inv cf IFRSInterimDuration-JPY
Expenditures by deposit of deposits inv cf IFRSPrior1InterimDuration-7700000000JPY
Expenditures by deposit of deposits inv cf IFRSInterimDuration-JPY
Other inv cf IFRSPrior1InterimDuration650000000JPY
Other inv cf IFRSInterimDuration624000000JPY
Net cash provided by used in investing activities IFRSPrior1InterimDuration-61556000000JPY
Net cash provided by used in investing activities IFRSInterimDuration53663000000JPY
Net increase decrease in short term borrowings fin cf IFRSPrior1InterimDuration101000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2025-12-31pass rounding
balance sheet identityconsolidated 2026-06-30pass
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2025-01-01/2025-06-30pass
statement vs summary · net income attributable to parentconsolidated 2026-01-01/2026-06-30pass
statement vs summary · operating cash flowconsolidated 2025-01-01/2025-06-30pass
statement vs summary · operating cash flowconsolidated 2026-01-01/2026-06-30pass
statement vs summary · revenueconsolidated 2025-01-01/2025-06-30pass
statement vs summary · revenueconsolidated 2026-01-01/2026-06-30pass
statement vs summary · total assetsconsolidated 2025-12-31pass
statement vs summary · total assetsconsolidated 2026-06-30pass